Three approved biologics already compete in chronic spontaneous urticaria — dupilumab, omalizumab, and tezepelumab casting a long shadow over asthma — and Jasper Therapeutics is now signaling it cannot fund its way to a fourth. The board’s formal review of strategic alternatives, announced June 1, is not a negotiating posture; the company’s own filings cite an “imminent need” to raise additional capital and a going-concern risk that makes the Phase 2b/3 CSU trial contingent on outside money arriving. That is the real asymmetry here: briquilimab has posted positive clinical signals in CSU, chronic inducible urticaria, and allergic asthma, yet the asset sits inside a shell that may not survive long enough to generate the pivotal readout acquirers actually need.
The strategic logic for a buyer is straightforward but conditional. Briquilimab depletes mast cells at the receptor level by blocking stem cell factor binding to KIT — a mechanism upstream of IgE and IL-4/IL-13 pathways that the current market leaders exploit. That differentiation is real. In a CSU market projected to exceed $4 billion globally by the end of the decade, a mechanism that addresses patients who cycle through omalizumab is commercially meaningful. The problem is that “demonstrated efficacy and safety in patients and healthy volunteers” is not a Phase 3 readout, and no large pharma allergology or immunology franchise will pay full value for an asset that still needs a confirmatory trial, particularly when the seller is in cash-preservation mode and cannot run that trial independently.
That cash pressure actually defines the deal terms more than the science does. A fire-sale asset licensing arrangement — the first option listed in the review — would generate near-term liquidity but surrender the upside that makes briquilimab interesting in the first place. A full acquisition by an immunology-focused buyer like Sanofi, AstraZeneca, or Regeneron would price in trial execution risk as a discount, not a premium. A business combination with another small-cap burning in the same space merely redistributes the problem. Wind-down is the explicit backstop, which tells the market the board views doing nothing as a real probability, not a legal formality.
The single number to watch is Jasper’s remaining cash runway — specifically, whether the next quarterly filing shows enough operating capital to keep the Phase 2b/3 CSU enrollment active through an interim data cut. If enrollment pauses before that interim, the asset’s negotiating leverage collapses entirely, and whatever transaction emerges will reflect the price of desperation rather than differentiated mechanism.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
